Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report

Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more

By Paul Bonanos, Director of Biopharma Intelligence
February 13, 2025 9:51 PM UTC

Longwood Fund has launched Newleos, a start-up with $93.5 million in cash to support development of a portfolio of neuropsychiatric assets in-licensed from Roche — including some that are ready for proof-of-concept studies.

Goldman Sachs led the series A round of funding for Newleos Therapeutics Inc., with the firm’s Ming Cheah taking a board seat. The team also includes Longwood Founding Partner Christoph Westphal as executive chairman and Longwood Executive Partner David Donabedian as CEO...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Abcuro Inc.